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Abstract
Kaposi’s sarcoma (KS) is the most common tumor
affecting AIDS patients with over 20% of these patients
afflicted by this disease. Previous studies have dem-
onstrated that KS tumor cells predominantly express
the prosurvival protein Bcl-XL compared with Bcl-2. In
the current study, we have used an adenoviral vector
that expresses Bcl-XS, a functional inhibitor of Bcl-XL,
to study the significance of Bcl-XL expression in the KS
cell line (SLK) or KS primary cultures. The results
demonstrate that 75% to 80% of SLK or KS primary cells
were killed by the Bcl-XS containing adenovirus where-
as KS cells infected with control adenovirus showed no
significant cell death or growth inhibition. Overexpres-
sion of Bcl-XL, but not Bcl-2, in SLK cells attenuated
apoptosis induced by adenovirus Bcl-XS. Immunopre-
cipitation experiments revealed that adenoviral Bcl-XS
associated with Bcl-XL, but not with Bcl-2. Mutational
analysis showed that the 2 helical region of Bcl-XS
containing the BH3 motif was critical for killing activity
and interaction with Bcl-XL. These results suggest
that Bcl-XS is a direct killer and Bcl-XL may act by
interacting with and sequestering Bcl-XS. These stud-
ies also suggest that targeting Bcl -XL may be of
therapeutic benefit for the treatment of tumors that
are characterized by inappropriate expression of Bcl-
XL. Neoplasia (2001) 3, 437–445.
Keywords: Apoptosis, Bcl - 2, Bcl - X, adenovirus, Kaposi’s sarcoma.
Introduction
Apoptosis, a common form of programmed cell death, is
essential during development and tissue homeostasis and
plays a role in the pathogenesis of a variety of diseases
[1]. Members of the Bcl -2 family that include prosurvival
and proapoptotic proteins have been recognized as key
regulators of the apoptotic process [2]. Several members
of the family including Bcl -2 and Bcl -XL have been shown
to protect cells from apoptosis induced by a wide array of
stimuli, whereas other members of this family such as Bax,
Bak, and Bad have been shown to promote cell death [2 ].
In addition to prosurvival Bcl -XL, the bcl -x gene can
encode several protein products including Bcl -XS as a
result of alternative splicing [3–6]. Bcl -XS is a proapoptotic
protein that lacks BH1 and BH2 domains [3], which have
been shown to be important in mediating the prosurvival
function of prosurvival Bcl -2 family members including Bcl -
XL [7,8 ]. bcl -XS mRNA levels have been shown to be
upregulated before apoptosis associated with mammary
tissue involution in mice and ischemia in rat brain [9,10].
Bcl -XS has been reported to inhibit the protective function
of Bcl -2 and Bcl -XL against apoptosis induced by growth
factor deprivation and chemotherapeutic drugs [3,11,12].
Furthermore, expression of Bcl -XS has been shown to
promote apoptosis or nonapoptotic cell death in several
experimental systems [13–16].
It has been postulated that overexpression of cell
survival proteins may contribute to neoplasia by blocking
apoptosis in premalignant or transformed cells. Many cells
overexpress Bcl -2 or Bcl -XL, and this overexpression has
been found to correlate with poor prognosis and resistance
to treatment in several types of malignancies [17]. Kaposi’s
sarcoma (KS), a neoplasm with multifocal vascular lesions,
is the most common tumor in AIDS patients, afflicting up to
30% of HIV-1–positive patients [18,19]. It has been
recently demonstrated that the majority of primary KS
tumors overexpress Bcl -XL [20] but also can express Bcl -
2 [21]. As these proteins are known to inhibit cell death,
expression of these antiapoptosis Bcl -2 family members in
KS cells may contribute to the prolonged survival of the
tumor cells in vivo.
We previously constructed an adenoviral vector that
encodes for the Bcl -XS protein, and showed that primary
carcinoma cells as well as cell lines derived from multiple
epithelial tumors were killed following infection with this
adenovirus in the absence of an exogenous apoptotic signal
[14]. However, the effect of Bcl -XS expression in sarcoma
cells is unknown. Furthermore, the mechanism by which Bcl -
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XS promotes cell death remains poorly understood. In this
report, we demonstrate that Bcl -XS expression induces
apoptosis of KS cells. Significantly, Bcl -XL but not Bcl -2
attenuated the proapoptotic activity of the bcl -XS adenovi-
rus. Consistent with this finding, Bcl -XL but not Bcl -2,
associated with Bcl -XS in extracts of KS cells. We also
provide evidence that the BH3 motif of Bcl -XS is critical for
Bcl -XL binding and killing activity, suggesting that Bcl -XS
acts at least in part by antagonizing the prosurvival function
of Bcl -XL.
Materials and Methods
Cells and Cell Culture
KS cell line (SLK) established from a tumor biopsy
from oral mucosa of an iatrogenically immunosuppressed
HIV-negative man [22] was obtained from Dr. J. Levy
(University of California, San Francisco). The cells were
maintained in culture using RPMI 1640 medium contain-
ing 10% heat- inactivated fetal bovine serum. For
passage, the cells were treated with 0.05% trypsin–
0.53 mM EDTA, washed, and replated. Three different
human KS cell cultures were isolated from KS tumors of
HIV-positive patients and designated as KS21B, KS23B,
and KSL100S as described [23,24]. The other primary
KS cell line KSPG38 [25] was obtained from Dr. P. Gill
(University of Southern California, Los Angeles). Cells
were plated on tissue culture dishes (Corning, Corning,
NY) coated with attachment factor (Cell Systems,
Kirkland, WA) and were maintained in RPMI 1640 and
20% heat- inactivated fetal bovine serum supplemented
with 10% nutridoma HU (Boehringer Mannheim Bio-
chemicals, Indianapolis, IN), 2 mM L-glutamine, 100 U/
ml penicillin, 100 g/ml streptomycin, 50 g/ml genta-
micin, 50 g/ml endothelial cell growth supplement ( ICN
Biochemicals, Aurora, OH), and 16 U/ml bovine
heparin.
Infection of Cells with Recombinant Adenoviruses
The bcl -XS [14] and control E1-deleted adenovirus [26]
were prepared as previously described [14] and the number
of adenovirus particles in viral stocks was determined by
spectrophotometry. SLK cells were infected with a stock of
the beta-galactosidase adenovirus [14] of known titer, and
then stained with 5-bromo-4-chloro-3- indolyl  -D-galacto-
Figure 1. Adenoviral Bcl -XS kills SLK cells. (A ) Cells were infected either with control or bcl -XS adenovirus for 72 hours and the expression of Bcl -XS protein was
analyzed by immunoblotting. Note that the cells infected with the virus expressed Bcl -XS protein whereas the level of endogenous Bcl -XL protein remained
unaltered. (B ) SLK cells were infected with adenovirus and at day 3, 6, or 9, the number of viable cells ( adhering and nonadhering cells ) were determined by trypan
blue exclusion. Results are shown as themean±SEM of triplicate cultures. * / **Indicates P values less than .05 / .01, respectively compared with the results of control
virus infected cells.
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side to determine the number of viral particles per cell
needed to infect approximately 85% to 95% of the cells. For
adenoviral infection, SLK cells or KS primary cultures were
exposed to the adenovirus vectors for 4 hours in serum-free
medium in a small volume sufficient to cover the monolayer
culture. Following incubation, 2% serum containing medium
was added and incubated overnight. Next day, the medium
was removed and replaced with medium containing 10%
serum. Each infection was performed at least in triplicate. At
the end of desired length of incubation, cell viability of virally
infected cell was determined by trypan blue exclusion and
cell growth was assessed by hemocytometry. Statistical
significance was calculated by Student’s paired t test. P
values less than .05 are considered to be statistically
significant.
Plasmids
pcDNA3 plasmids containing Flag or HA- tagged bcl -XL
or bcl -2 have been described [27]. Plasmids to express
wild- type and mutant Bcl -XS were generated by a polymer-
ase chain reaction method using appropriate oligonucleotide
primers complementary to the human bcl -XS sequence and
ligated to pcDNA-HA [27]. The authenticity of the constructs
was confirmed by DNA sequencing.
Transfection, Immunoprecipitation, and Immunoblotting
SLK cells were transfected by the calcium phosphate
method with 10 g of the pcDNA3-neo plasmid containing
either Flag- tagged bcl -XL or bcl -2. Individual cell clones
were selected for growth in the presence of G418 (1.5
mg/ml). For immunoprecipitation, cells were lysed in
Nonidet P-40 isotonic lysis buffer and lysates were
incubated with 1 g/ml anti -Flag antibody or normal rabbit
IgG overnight at 48C with 5% (vol /vol ) of protein A-
sepharose 4B (Zymed Laboratories, South San Francisco,
CA). Immune complexes were centrifuged, washed four
times with excess cold Nonidet P-40 isotonic lysis buffer,
separated on a 12% SDS–polyacrylamide gel and
immunoblotted with relevant antibodies as described
[27]. Rabbit polyclonal anti–Bcl -X (gift from Dr. C.
Thompson, University of Pennsylvania) was used for the
detection Bcl -XL and Bcl -XS protein, whereas Bcl -2
protein was detected by anti–human Bcl-2 monoclonal
antibody, 6C8 (Pharmingen, San Diego, CA). Immunopre-
cipitations to assess the binding of Bcl -XS mutants to Bcl -
XL were performed in 293 sarcoma cell lysates prepared
after transient transfection as described above.
Apoptosis Assay
SLK cells were harvested at day 6 after infection with bcl -
XS adenovirus by combining floating cells in the media with
adherent cells that were detached with trypsin–EDTA in
PBS. Cells were suspended in a hypotonic buffer containing
propidium iodide and the percent of cells at sub-Go phase
was determined by flow cytometry [28]. For transient
assays, wild - type or mutant bcl -XS constructs were
cotransfected with a pCMV-galactosidase reporter plasmid
into 293 kidney sarcoma cells as reported [27]. Apoptosis
was determined 18 hours posttransfection in triplicate
cultures as reported [27].
Results
Bcl-XS is Expressed After Infection of SLK Tumor Cells with
bcl -XS Adenovirus
To verify that Bcl -XS protein is expressed after treatment
of the SLK cell line with the bcl -XS adenovirus, extracts from
cells infected with various concentrations of control and bcl -
XS adenovirus were immunoblotted with an antibody that
recognizes both Bcl -XS and Bcl -XL. Forty -eight hours after
infection, a dose-dependent increase in Bcl -XS expression
was observed (Figure 1A ). The Bcl -XS protein was detected
as a doublet, which is consistent with a previous report [12].
Bcl -XS was undetectable in extracts from uninfected cells or
cells infected with equivalent titers of control adenovirus
(Figure 1A ). After treatment of SLK cells with control or bcl -
Figure 2. Viability and morphologic changes of SLK cells following treatment
with control adenovirus or bcl -XS adenovirus (A ). Photomicrographs (400 )
of a representative field of SLK cells were taken on days 3 and 8 after virus
infection. Morphology of cells infected with control adenovirus (not shown )
were not different from untreated control. ( B ) Cell cycle profile was
determined in untreated cells, cell infected with control adenovirus, or with
bcl -XS adenovirus using 2000 pfu / cell at 72 hours post infection.
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XS adenovirus, the levels of endogenous Bcl -XL were
unaffected when compared with those of uninfected SLK
cells (Figure 1A ).
The bcl -XS Adenovirus Inhibits Cell Growth and Induces
Cell Death in SLK Tumor Cells
SLK cells infected with control adenovirus at 2000 or
5000 pfu/cell showed no cytostatic effects on growth as
compared with untreated cells when assessed at days 3, 6,
and 9 after infection (Figure 1B ). In contrast, exposure of
SLK cells to the bcl -XS adenovirus at 1000 or 2000 pfu/
cell resulted in progressive loss of cell growth and reduced
cell viability (Figure 1B ). By day 3 after infection, a
significant percentage of the SLK tumor cells infected with
the bcl -XS adenovirus displayed rounded-up morphology;
by day 8, the great majority of the cells become
fragmented and floated in the dish, whereas cells treated
with control adenovirus (data not shown) or cells left
untreated remained attached to the dish and were viable
(Figure 2A ). Apoptotic cells undergo DNA fragmentation,
an event that can be assessed by staining of nuclear DNA
[31]. To determine if induction of cell death by the bcl -XS
adenovirus was associated with loss of DNA integrity, we
performed flow cytometric analysis of nuclei stained with
propidium iodide. In a representative experiment, we found
that about 40% of the cells infected with the Bcl -XS
adenovirus for 72 hours exhibited a sub-Go DNA profile,
which is characteristic of apoptotic cells, as opposed to
about 10% apoptotic cells in untreated cultures or SLK
cells infected with control virus (Figure 2B ). These results
suggest that the bcl -XS adenovirus induces apoptosis in
KS cells.
Bcl-XS Containing Adenovirus Kills Primary KS Cells
As SLK cells could be killed efficiently by adenovirus bcl -
Xs, we extended our studies to primary cultures of KS tumor
cells to validate our observations made with the KS cell line.
Infection of four independent primary cultures of KS tumor
cells with the bcl -XS adenovirus resulted in marked
cytotoxicity of tumor cells when compared to uninfected
cells or cells treated with control adenovirus (Figure 3 ). To
determine the expression levels of Bcl -2 and Bcl -XL in these
KS tumor cells, extracts were prepared and subjected to
immunoblotting with anti–Bcl -2 and anti–Bcl -X antibodies.
The analysis showed that all the KS tumor cell cultures
tested (KS21B, KS23B, KS PG38, and KSL 100S)
expressed Bcl -XL at varying levels, whereas Bcl -2 was
detectable only in KS 23B cells (data not shown).
Figure 3. Cell viability of primary cultures of KS tumor cells infected with bcl -XS adenovirus and expression of Bcl -XL and Bcl - 2 proteins in primary cultures of KS
tumors. KS cells (KS21B, KS23B, PG38, and KSL100S ) were infected with either control adenovirus ( 2000 pfu / cell ) or bcl -XS (pfu / cell indicated in the figure ) as
described in the Materials and Methods section. At day 8, cell viability of untreated or virally infected cells were determined by trypan blue exclusion and cell numbers
were assessed by hemocytometry. *Indicates P values less than .01 compared with cells infected with control virus.
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Bcl-XL but Not Bcl -2 Protects SLK Tumor Cells from Cell
Death Mediated by the bcl -XS Adenovirus
Primary cultures of KS cells can express Bcl -XL (Ref.
[20] and in this study) and Bcl -2 [21]. To determine if Bcl -
XL or Bcl -2 can regulate killing mediated by the bcl -XS
adenovirus, we transfected the SLK cell line with expression
plasmids producing Flag- tagged Bcl -XL, Flag- tagged Bcl -2
or control plasmid and identified two stable clones that
overexpress Bcl -XL or Bcl -2. Flow cytometric analysis using
anti -Flag antibody showed that the clones expressed Flag-
tagged Bcl -XL or Bcl -2 in virtually all cells (Figure 4A ).
Western blot analysis confirmed that the clones expressed
Flag-Bcl -XL or Flag-Bcl -2, although the levels of Bcl -2
were higher than those of Bcl -XL (Figure 4B ). To determine
if exogenous Bcl -XL and Bcl -2 provide increased survival,
SLK cells transfected with plasmids producing these
prosurvival proteins or plasmid control were exposed to the
chemotherapeutic drug etoposide and cell viability was
assessed after drug exposure. Approximately 70% to 75%
of the SLK cells lost their viability after incubation with
etoposide for 2 days (Figure 4C ). By contrast, SLK cells
overexpressing Bcl -XL or Bcl -2 showed increased survival
after treatment with the drug (Figure 4C ). To determine
whether Bcl -XL or Bcl -2 could modulate cell killing induced
by the bcl -XS adenovirus, SLK tumor cells stably transfected
with these prosurvival genes or control plasmid were infected
with the bcl -XS adenovirus and cell viability was assessed at
different times after adenovirus infection. As seen in Figure
5, expression of Bcl -XL promoted the survival of SLK cells
after infection with the bcl -XS adenovirus whereas Bcl -2 did
not.
Bcl-XL but Not Bcl -2 Interact with Bcl -XS After Infection of
SLK Cells with Adenovirus bcl -XS
To gain insight into the mechanism by which Bcl -Xs
mediates killing of KS cells, we prepared protein extracts
from control and adenovirus bcl -XS–infected SLK cells and
immunoprecipitated Bcl -XL and Bcl -2 complexes with anti -
Flag antibody. Immunoblotting analysis of control, Bcl -XL,
and Bcl -2 immunoprecipitates with anti–Bcl -X antibody
Figure 4. Expression of functional Bcl -XL and Bcl - 2 in SLK cell clones. (A ) Immunoblotting analysis for Flag -Bcl - 2 and Flag -Bcl -XL using anti - Flag monoclonal
antibody. Immunoblotting for beta - tubulin was used as a loading control. Note that the SLK-Neo control does not express either Flag -Bcl -XL or Flag -Bcl - 2. (B )
Fluorescence histograms of SLK clones. Clones expressing Flag -Bcl -XL or Flag -Bcl - 2 were analyzed for Flag - epitope expression by flow cytometry with anti -
Flag monoclonal antibody. Controls are SLK clones expressing Flag -Bcl -XL or Flag -Bcl - 2 stained with isotype -matched control IgG. (C ) Cell survival of SLK
clones after treatment with etoposide. SLK clones were treated with etoposide (2 g /ml ) and cell viability was determined on days 1 and 2 after continuous exposure
to the drug. Results shown are the mean±SD of triplicate cultures and are representative of at least two separate experiments.
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revealed that Bcl -XS associated with Bcl -XL but not with
Bcl -2 (Figure 6 ). Immunoblotting of total lysates with anti–
Bcl -X antibody showed that adenoviral Bcl -XS was
expressed in both Bcl -XL and Bcl -2 transfectants indicating
that the lack of association of Bcl -XS with Bcl -2 cannot be
explained by differential expression of Bcl -XS in SLK cells
(Figure 6 ).
The BH3 Motif and the C-Terminal Transmembrane
Domain of Bcl -XS are Critical for Killing Activity
We generated a panel of Bcl -XS deletion mutants based
on the known crystal structure of Bcl -XL [29] to determine
the regions that are important for killing activity. These
included Bcl -XS mutants with internal deletion of the BH4
domain (residues 2 to 37), flexible loop region ( residues 38
to 62), BH3 domain ( residue 86 to 98), most of the 2, 4,
and 7 helical region (residues 116 to 132), and the C-
terminal transmembrane domain (residues 144 to 170)
(Figure 7A ). Immunoblotting analysis of cell extracts from
human 293 kidney sarcoma cells transiently transfected with
Bcl -XS expression constructs revealed that the mutants
were expressed in transfected cells (Figure 7B ). Functional
analysis showed that residues 86 to 98 (BH3 domain) and
themembrane anchoring domain of Bcl -XS were required for
killing activity (Figure 7C ). Expression of baculovirus p35, a
caspase inhibitor, suppressed apoptosis induced by wild-
Figure 5. Viability of SLK cells overexpressing Bcl -XL or Bcl - 2. Cells were infected with control adenovirus or bcl -XS adenovirus at different pfu / cell ( indicated in
the figure ) and cell viability was determined at day 8. The results are presented as percent of viable cells relative to that of untreated cells that was considered as
being 100%. *Indicates P values less than .01 compared with neo - transfected SLK cells.
Figure 6. Differential interaction of Bcl -XL and Bcl - 2 with Bcl -XS. SLK cells expressing Flag - tagged Bcl -XL or Bcl - 2 were exposed to bcl -XS adenovirus and for
control, SLK cells expressing Flag - tagged Bcl -XL were exposed to E1 -deleted adenovirus (pfu / cell indicated in the figure ) for 72 hours. Extracts from infected cells
were immunoprecipitated with anti - Flag or control antibody as described in methods and immunoprecipitates were immunoblotted with rabbit polyclonal against
Bcl -X.
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type Bcl -XS (Figure. 7C ), suggesting that the proapoptotic
activity of Bcl -XS is mediated through caspases.
The BH3 Domain of Bcl -XS is Required for Interaction with
Bcl -XL
We next determined the region of Bcl -XS that is required
for Bcl -XL binding. In these experiments, we coexpressed
Bcl -XS and Bcl -XL by transient transfection in 293 cells and
immunoprecipitated Bcl -XL with anti -Flag antibody. The
analysis in Figure 8 revealed that all mutants except Bcl -XS
(86–98) coimmunoprecipitated with Bcl -XL, indicating that
the BH3 domain of Bcl -Xs is required for the interaction with
Bcl -XL.
Discussion
We report here that KS tumor cells undergo cell death after
infection with a replication-deficient adenoviral vector that
expresses Bcl -XS. Adenoviral vector expressing Bcl -XS
caused cell death as early as 3 days after infection of the SLK
cell line and several primary cultures of KS cells. Bcl -XS
lacks BH1 and BH2 but contains BH3 and BH4 domains. As
it has been shown for BH3-only Bcl -2 family members, such
as Bad and Hrk [27,30], the BH3 domain of Bcl -XS may
mediate apoptosis by its ability to heterodimerize, with and
inactivate prosurvival Bcl -2 family proteins. Consistent with
this hypothesis, our mutational analyses revealed a correla-
tion between Bcl -XS killing activity and the ability of Bcl -Xs to
bind Bcl -XL. In these experiments, the BH3 domain of Bcl -
XS was required for both Bcl -XL binding and killing activity. In
agreement with our results, it has been shown that only
mutant forms of Bcl -XS that contain the BH3 domain can
antagonize the prosurvival function of Bcl -XL against Bax-
mediated apoptosis [12]. The ability of Bcl -XS to hetero-
dimerize with Bcl -XL has been controversial [11], although
recent experiments support our observation that Bcl -XS
interacts with Bcl -XL [12]. In contrast, Bcl -XS did not
associate with Bcl -2 in SLK cells infected with the Bcl -XS
adenovirus. Consistent with these findings is our observation
that cell death induced by the bcl -XS adenovirus was
partially inhibited by Bcl -XL but not by Bcl -2.
Primary cultures of KS tumor cells or SLK cells, although
expressing constitutive levels of Bcl -XL were susceptible to
apoptosis induced by adenovirus Bcl -XS. Similarly, the bcl -
XS adenovirus induced apoptosis in neuroblastoma cells that
overexpress Bcl -XL [31]. It is possible that the constitutive
levels of Bcl -XL may not be sufficiently high to bind all the
exogenous Bcl -XS. However, even after transfection of Bcl -
XL into SLK cells, the bcl -XS adenovirus induced cell death
although at a reduced rate compared to controls. Another
possibility is that Bcl -XS is a direct killer that mediates cell
death that is in part independent of Bcl -XL. Although this
latter mechanism needs to be further investigated, it may
involve binding to mitochondria and disruption of mitochon-
drial integrity [16], as postulated for other BH3-containing
proapoptotic molecules [32,33]. In this model, Bcl -XL
inhibits Bcl -XS activity by interacting with and sequestering
Bcl -XS. It is most likely that Bcl -XS acts directly to kill cells,
because if it acted through other proapoptotic molecules,
such as Bax or Bak, Bcl -2 might be expected to interfere with
Bcl -XS. Our studies have demonstrated that all the primary
cultures tested thus far have been effectively killed by the
adenovirus bcl -XS. Considering the aggressive nature of
AIDS-KS and the lack of currently available effective
treatment, inhibition of Bcl -XL activity may be of benefit for
the treatment of this potentially fatal disease. Although the
bcl -XS adenovirus may be effective in the treatment of
superficial tumors, effective inactivation of Bcl -XL will require
different approaches with improved delivery of therapeutic
molecules to tumor cells. Recent studies have identified
small molecules that induce apoptosis by binding to the
BH3-binding pocket of Bcl -XL and blocking BH3 domain–
mediated heterodimerization between Bcl -2 family members
[34,35]. These studies suggest that it may be possible to
effectively target the Bcl -XL survival pathway in diseases
such as KS that are characterized by aberrant expression of
prosurvival Bcl -2 family members.
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